<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17481" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ampicillin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Peechakara</surname>
            <given-names>Basil V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Basit</surname>
            <given-names>Hajira</given-names>
          </name>
          <aff>Brookdale University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Basil Peechakara declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hajira Basit declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17481.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ampicillin is a medication used to manage and treat certain bacterial infections. It is in the penicillin class of medications. Ampicillin was developed to overcome the issue of drug resistance and extend the antimicrobial coverage of penicillins. It is also resistant to acid so it can be administered orally. This activity outlines the indications, action, and contraindications for ampicillin as a valuable agent in treating certain bacterial infections like those from E. coli, S. aureus, S. pneumoniae, H. influenzae, etc. In addition, this activity will highlight the mechanism of action, adverse event profile, off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional team members in treating patients with infections caused by susceptible bacteria.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for the use of ampicillin.</p></list-item><list-item><p>Describe the mechanism of action of ampicillin.</p></list-item><list-item><p>Review the adverse effects associated with the use of ampicillin.</p></list-item><list-item><p>Outline the role of interprofessional coordination in restricting unwarranted use of ampicillin and other antimicrobials.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17481&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17481">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17481.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Penicillins had been very effective against&#x000a0;<italic toggle="yes">S. aureus;</italic>&#x000a0;in the past, however,&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>&#x000a0;has become capable of exhibiting resistance against them by producing a penicillin hydrolyzing enzyme &#x02013; penicillinase. After that, ampicillin was developed to overcome this issue and extend the antimicrobial coverage of penicillins. It is also resistant to acid so it can be administered orally.<xref ref-type="bibr" rid="article-17481.r1">[1]</xref></p>
        <p>Ampicillin has effective minimum inhibitory concentration for most of medically important organisms in infectious disease like&#x000a0;<italic toggle="yes">Escherichia coli</italic>: MIC = 4 mg/L,&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>: MIC = 0.6-1 mg/L,&#x000a0;<italic toggle="yes">Streptococcus pneumoniae</italic>: MIC = 0.03-0.06 mg/L,&#x000a0;<italic toggle="yes">Hemophilus influenzae</italic>: MIC = 0.25 mg/L.<xref ref-type="bibr" rid="article-17481.r1">[1]</xref>&#x000a0;To reduce the development of drug-resistant bacteria and maintain the&#x000a0;effectiveness of ampicillin should be used only to treat infections that are proven or&#x000a0;strongly suspected to be caused by bacteria.</p>
        <p>
<bold>FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Respiratory tract infection:&#x000a0;</bold>caused by:&#x000a0;<italic toggle="yes">Streptococcus pneumoniae</italic>, penicillinase, and non-penicillinase-producing&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>, group A beta-hemolytic Streptococci,&#x000a0;<italic toggle="yes">Hemophilus influenzae</italic>.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Bacterial meningitis:&#x000a0;</bold>caused by Gram-negative bacteria:&#x000a0;<italic toggle="yes">Neisseria meningitis</italic>,&#x000a0;<italic toggle="yes">Escherichia coli</italic>, Gram-positive bacteria:&#x000a0;<italic toggle="yes">Listeria</italic>&#x000a0;<italic toggle="yes">monocytogenes,&#x000a0;Group B Streptococci</italic>. Adding aminoglycosides increases its effectiveness against gram-negative bacteria.<xref ref-type="bibr" rid="article-17481.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Septicemia and endocarditis:&#x000a0;</bold>caused by Gram-positive bacteria, including penicillin-susceptible&#x000a0;<italic toggle="yes">Staphylococcus species</italic>,&#x000a0;<italic toggle="yes">Streptococcus</italic>&#x000a0;<italic toggle="yes">species</italic>, and&#x000a0;<italic toggle="yes">Enterococcus species. Gram-negative</italic>&#x000a0;bacteria include&#x000a0;<italic toggle="yes">Escherichia coli</italic>,&#x000a0;<italic toggle="yes">Salmonella</italic>&#x000a0;<italic toggle="yes">species</italic>, and&#x000a0;<italic toggle="yes">Proteus mirabilis</italic>. Endocarditis caused by enterococci usually responds to intravenous ampicillin. Adding aminoglycosides with ampicillin may increase its effectiveness when treating endocarditis caused by streptococci.<xref ref-type="bibr" rid="article-17481.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Genitourinary infections:</bold>&#x000a0;caused by sensitive strains of&#x000a0;<italic toggle="yes">Escherichia coli</italic>&#x000a0;and&#x000a0;<italic toggle="yes">Proteus mirabilis</italic>. The CDC no longer recommends ampicillin&#x000a0;as a first-line agent in treating gonorrhea.<xref ref-type="bibr" rid="article-17481.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Gastrointestinal infections:</bold>&#x000a0;caused by&#x000a0;<italic toggle="yes">Salmonella typhi</italic>,&#x000a0;<italic toggle="yes">Shigella</italic>&#x000a0;<italic toggle="yes">species</italic>, and other&#x000a0;<italic toggle="yes">Salmonella</italic>&#x000a0;<italic toggle="yes">species</italic>, and usually improve with oral or intravenous therapy. Culture must be obtained for susceptibility and antimicrobial sensitivity; however, the clinician may start empiric treatment before receiving the results.<xref ref-type="bibr" rid="article-17481.r5">[5]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Off-label Clinical Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Neonatal g<italic toggle="yes">roup B Streptococcal </italic>infection</bold><italic toggle="yes"><bold>&#x000a0;</bold></italic><bold>prophylaxi</bold><bold>s:</bold>&#x000a0;Administered as an alternative to intramuscular penicillin.<xref ref-type="bibr" rid="article-17481.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Prophylaxis in surgery<italic toggle="yes">:&#x000a0;</italic></bold>Ampicillin is a routinely selected agent in orthopedic surgeries, especially prosthetic implants and dental surgeries.<xref ref-type="bibr" rid="article-17481.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Chorioamnionitis: </bold>Ampicillin, in combination with gentamicin, is&#x000a0;used to treat&#x000a0;chorioamnionitis.<xref ref-type="bibr" rid="article-17481.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Carbapenem-resistant&#x000a0;<italic toggle="yes">Acinetobacter baumannii&#x000a0;</italic>(CRAB):</bold> According to IDSA 2022 guidelines, ampicillin/sulbactam is the preferred agent for the infection caused by carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic>(CRAB).<xref ref-type="bibr" rid="article-17481.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17481.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ampicillin is a beta-lactam antibiotic and is classified as aminopenicillins.</p>
        <list list-type="bullet">
          <list-item>
            <p>The mode of action of beta-lactam antimicrobials on sensitive organisms can be considered a two-step process: In the first step, the drug binds to primary receptors called membrane-bound penicillin-binding proteins (PBPs). These proteins perform vital roles in cell cycle-related; formation of cell wall peptidoglycan structure. Therefore, the inactivation of PBPs by bound antimicrobials immediately affects their function.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The second stage comprises the physiological effects caused by this receptor-ligand interaction. PBPs are involved in the cell wall's late stages of peptidoglycan synthesis. Because peptidoglycan maintains the integrity of the cell wall, which resides in a hypotonic environment, its disruption causes lysis and cell death.<xref ref-type="bibr" rid="article-17481.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>It is important to recognize that ampicillin is primarily bactericidal against susceptible bacteria due to its inhibition of cell wall synthesis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mechanism of resistance: Penicillinase (a &#x003b2;-lactamase) cleaves the beta-lactam ring and results in&#x000a0;resistance to ampicillin. Hence ampicillin is usually&#x000a0;combined&#x000a0;with &#x003b2;-lactamase inhibitors like sulbactam.<xref ref-type="bibr" rid="article-17481.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption:&#x000a0;Ampicillin injection diffuses readily in body tissues and fluids.&#x000a0;</p>
        <p>Distribution:&#x000a0; Ampicillin shows low plasma protein binding(20%)) compared to 60 to 90% for other penicillins.&#x000a0;Enhanced penetration through the blood-brain barrier and adequate CSF concentration is achieved&#x000a0;due to inflammation in meningitis.<xref ref-type="bibr" rid="article-17481.r12">[12]</xref></p>
        <p>Metabolism:&#x000a0;Ampicillin is excreted largely unchanged in the urine, and its excretion can be delayed by concurrent administration of probenecid.&#x000a0;</p>
        <p>Excretion:&#x000a0;The half-life of ampicillin is 0.7 to 1.5 hours in adults with normal kidney function. According to a recent study, the pharmacokinetics of ampicillin vary&#x000a0;significantly in late preterm and term neonates; clinicians should be cautious when administering ampicillin to preterm neonates.<xref ref-type="bibr" rid="article-17481.r13">[13]</xref></p>
      </sec>
      <sec id="article-17481.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ampicillin administration can be oral, intramuscular, or intravenous.&#x000a0;Parenteral administration is preferable for severe or moderately severe infections. The oral route should not be the initial therapy in life-threatening conditions but can follow after parenteral therapy.</p>
        <p>
<bold>Oral Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>When administered orally, it should be on an empty stomach with 1 or 2 full glasses of water to increase absorption.</p>
          </list-item>
        </list>
        <p>
<bold>Intravenous Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For intravenous administration, ampicillin may be administered as an IV bolus. Reconstitution of vials containing 125, 250, or 500 mg of the drug with 5 ml sterile water is recommended.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vials containing 1 or 2 g should be reconstituted at 7.4 or 14.8 ml of bacteriostatic or sterile water.</p>
          </list-item>
        </list>
        <p>
<bold>Intramuscular Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>If administering ampicillin intramuscularly, the injection should be into a large muscle mass. Reconstitute with bacteriostatic or sterile water to create solutions containing 125 or 250 mg/ml.</p>
          </list-item>
        </list>
        <p>
<bold>Rate of Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Formulations reconstituted from 125, 250, or 500 mg vials must be given over 3 to 5 minutes by intravenous injection.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Formulations reconstituted from 1 or 2 g vials must be given over 10 to 15 minutes by intravenous injection.</p>
          </list-item>
        </list>
        <p>
<bold>GI Tract Infection</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bodyweight less than 40 kg: IV/IM 50 mg/kg/day every 6 to 8 hours</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bodyweight more than 40 kg: IV/IM 500 mg every 6 hours</p>
          </list-item>
        </list>
        <p>
<bold>GU Tract Infection</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bodyweight less than 40 kg: IV/IM 50 mg/kg/day every 6 to 8 hours</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bodyweight more than 40 kg: IV/IM 500 mg every 6 hours</p>
          </list-item>
        </list>
        <p>
<bold>Respiratory Tract Infection</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bodyweight less than 40 kg: IV/IM 250 to 500 mg/kg/day every 6 to 8 hours</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bodyweight more than 40 kg: IV/IM 25 to 50 mg/kg/day every 6 hours</p>
          </list-item>
        </list>
        <p>
<bold>Urinary Tract infection&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Caused by ampicillin susceptible <italic toggle="yes">enterococcus</italic></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IV/IM 1 to 2 g every 4 to 6 hrs</p>
          </list-item>
        </list>
        <p>
<bold>Bacterial Meningitis/Septicemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IV 150 to 200 mg/kg/day every every 6 to 8 hours</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Listeria</bold>
</italic>
<bold> Species</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IV 2 g every 4 hours<xref ref-type="bibr" rid="article-17481.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Endocarditis Prophylaxis (off-label)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In the respiratory tract, oral or dental procedure: IM, IV: 50 mg/kg as a single dose 30 to 60 minutes before the procedure.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In gastrointestinal or genitourinary procedure:&#x000a0;Only for patients at risk for endocarditis: IV/IM 2g 30 minutes before the procedure, followed by 1 g, 6 hours later with an aminoglycoside.</p>
          </list-item>
        </list>
        <p>
<bold>Endocarditis (off-label)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Endocarditis caused by <italic toggle="yes">Listeria species</italic></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IV/IM 200 mg/kg/day every 6 hours for 4 to 6 weeks&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Gonorrhea (not CDC recommended)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IV 3.5 g administered once with 1 g probenecid</p>
          </list-item>
        </list>
        <p>
<bold><italic toggle="yes">Streptococcus agalactiae&#x000a0;</italic>(off-label)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Maternal prophylaxis to prevent newborn infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IV first dose 2 g followed by 1 g every 4 hours till delivery<xref ref-type="bibr" rid="article-17481.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Patients with Hepatic Impairment: </bold>No dose adjustment has been provided in the manufacturer's labeling.</p>
        <p><bold>Patients with Renal Impairment:</bold> The dosing frequency should be adjusted based on patient CrCl.</p>
        <list list-type="bullet">
          <list-item>
            <p>CrCl &#x0003c;10 mL/min: Administer&#x000a0;every 12 to 24 hours</p>
          </list-item>
          <list-item>
            <p>CrCl 10-50 mL/min: Administer&#x000a0;every 6 to 12 hours&#x000a0;</p>
          </list-item>
          <list-item>
            <p>CrCl &#x0003e;50 mL/min: Administer every 6 hours.</p>
          </list-item>
        </list>
        <p><bold>Pregnancy Considerations: </bold>Ampicillin is widely used during pregnancy(Former FDA category B).&#x000a0;ACOG guidelines recommend that pregnant mothers with preterm&#x000a0;PROM(premature rupture of membranes)&#x000a0;should be treated with intravenous ampicillin and erythromycin, followed by oral antibiotics to decrease neonatal complications.<xref ref-type="bibr" rid="article-17481.r15">[15]</xref>&#x000a0;In addition, listeriosis during pregnancy has been associated with vertical transmission in newborns and higher mortality, for which ampicillin is often used&#x000a0;with other antibiotics.<xref ref-type="bibr" rid="article-17481.r16">[16]</xref>&#x000a0;</p>
        <p><bold>Breastfeeding Considerations:</bold>&#x000a0;Clinical data suggest that administration of ampicillin during lactation produces low levels in milk that are not anticipated to cause adverse effects in breastfed infants. However, alteration of the infant's gastrointestinal flora has been reported; consequently, when ampicillin is used during lactation, monitor for diarrhea and thrush.<xref ref-type="bibr" rid="article-17481.r17">[17]</xref></p>
      </sec>
      <sec id="article-17481.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Serious Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The primary adverse effects of ampicillin include seizure, enterocolitis, agranulocytosis, hemolytic anemia, immune thrombocytopenia, and pseudomembranous colitis.<xref ref-type="bibr" rid="article-17481.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Local Adverse Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pain at IM/IV injection site&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thrombophlebitis&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Hypersensitivity Reactions </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rashes and urticaria occur frequently.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reports also exist of some cases of erythema multiforme and exfoliative dermatitis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anaphylaxis is the most severe complication experienced and is usually associated with the parenteral form. Anaphylaxis is life-threatening and requires rapid treatment.<xref ref-type="bibr" rid="article-17481.r19">[19]</xref><xref ref-type="bibr" rid="article-17481.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stomatitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pseudomembranous colitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Enterocolitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Black hairy tongue</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mainly seen with oral dose administration).<xref ref-type="bibr" rid="article-17481.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hepatotoxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A moderate elevation of serum glutamic oxaloacetic transaminase (SGOT/AST) is reported, commonly in infants; its significance is unknown. Mild transient elevations are possible with repeated intramuscular administration in individuals receiving larger than usual doses. Evidence indicates that&#x000a0;AST gets released in the intramuscular injection site, and the increased quantities seen in the blood may not necessarily be from the liver as a source.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Isolated instances of idiosyncratic liver injury have been reported in persons receiving ampicillin.&#x000a0;The serum enzyme pattern is a hepatocellular pattern with marked elevations in ALT&#x000a0;and AST, minimal elevations in alkaline phosphatase, and rapid recovery after withdrawal.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In addition, cholestatic forms of hepatic injury with marked alkaline phosphatase elevations have also been infrequently described with vanishing bile duct syndrome.<xref ref-type="bibr" rid="article-17481.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Nephrotoxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Case reports of ampicillin-sulbactam-induced nephrotoxicity and AKI have been reported, mainly when used in combination with vancomycin.<xref ref-type="bibr" rid="article-17481.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Neurological&#x000a0;Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Seizures<xref ref-type="bibr" rid="article-17481.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hematological Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Reports exist of anemia, thrombocytopenic purpura, thrombocytopenia, eosinophilia, agranulocytosis, and leukopenia during ampicillin therapy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>These reactions are reversible on discontinuation of therapy, the etiology being a hypersensitive phenomenon.<xref ref-type="bibr" rid="article-17481.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Opportunistic Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>During therapy, superinfection with some bacteria or mycotic organisms is possible.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Opportunistic infection&#x000a0;warrants discontinuation of therapy and substitution of appropriate treatment.<xref ref-type="bibr" rid="article-17481.r26">[26]</xref><xref ref-type="bibr" rid="article-17481.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stevens-Johnson syndrome (SJS) has been reported&#x000a0;due to the concomitant use of ampicillin and allopurinol.<xref ref-type="bibr" rid="article-17481.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17481.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Infection by penicillinase-producing organisms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ampicillin is contraindicated in the treatment of infections caused by penicillinase-producing organisms. The rationale behind it is penicillinase&#x000a0;(beta-lactamase) will inactivate ampicillin.</p>
          </list-item>
        </list>
        <p>
<bold>Hypersensitivity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe and life-threatening anaphylactoid reactions can occur with penicillin therapy. Although anaphylaxis more commonly occurs following parenteral therapy, it can also present after oral administration. It is more likely in patients with a previous history of penicillin hypersensitivity and reaction to multiple allergens. Before initiating therapy, the clinician should carefully inquire about hypersensitivity reactions to cephalosporins, allergens, or penicillin.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If a hypersensitivity reaction occurs, the clinician should discontinue ampicillin therapy and initiate alternative antimicrobial therapy. Anaphylactoid reactions require immediate emergency treatment with oxygen, epinephrine, steroids, and airway management, including intubation(if clinically indicated).<xref ref-type="bibr" rid="article-17481.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold><italic toggle="yes">Clostridium Difficile </italic>Infection&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antibacterial treatment alters the intestine's natural flora, leading to the overgrowth of <italic toggle="yes">C. difficile</italic>. <italic toggle="yes">Clostridioides difficile-associated</italic>&#x000a0;diarrhea (CDAD) can occur with nearly all antibacterial agents, especially ampicillin. The resulting severity may range from mild diarrhea to fulminant colitis. Hypertoxin-producing <italic toggle="yes">C. difficile</italic> strains cause increased morbidity and mortality, as these strains are refractory to the recommended antimicrobial therapy and may require colectomy. Therefore, CDAD is a consideration for all patients who present with diarrhea after antibacterial use. Since it is reported to occur over two months after administering antibacterial agents, a careful medical history is necessary in these cases.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If CDAD is confirmed, ongoing antimicrobial use not directed against the organism might require cessation of therapy. Adequate fluid and electrolyte management, protein supplementation, and the antimicrobial regimen of <italic toggle="yes">C. difficile</italic> and surgical evaluation should be an option if indicated.<xref ref-type="bibr" rid="article-17481.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Concomitant Infectious Mononucleosis Infection</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A high proportion (43%) of patients with infectious mononucleosis started on ampicillin can develop a rash. Ideally, the rash appears 7 to 10 days following the initiation of ampicillin therapy and remains for a few days to one week after discontinuation of the drug. In most cases, the rash is maculopapular, generalized, and pruritic. Therefore, ampicillin administration is not a recommendation for these patients. Whether these patients are truly allergic to penicillin remains unknown.<xref ref-type="bibr" rid="article-17481.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Absence of Strong Indication</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ampicillin administration without a specific indication or proof of a bacterial infection or a prophylactic indication is not likely to benefit the patient. Instead, it increases the risk of the growth of drug-resistant bacteria.<xref ref-type="bibr" rid="article-17481.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17481.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>When prescribing&#x000a0;ampicillin for a long duration, monitor renal and hepatic function.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Additionally,&#x000a0;monitor&#x000a0;for signs and symptoms of anaphylaxis during the first dose.<xref ref-type="bibr" rid="article-17481.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Providers should carefully&#x000a0;monitor the parenteral solution for particulate matter and discoloration and discard it if needed.<xref ref-type="bibr" rid="article-17481.r32">[32]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17481.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <list list-type="bullet">
          <list-item>
            <p>Neurological adverse reactions, including convulsions, may occur due to high CSF&#x000a0;concentrations&#x000a0;of ampicillin.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Management of overdose requires medication discontinuation, symptomatic treatment, and supportive care.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Previously, whole bowel irrigation has been reported to be effective in severe cases of oral overdoses.<xref ref-type="bibr" rid="article-17481.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients with decreased renal function, ampicillin is removable via hemodialysis but not peritoneal dialysis.<xref ref-type="bibr" rid="article-17481.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In case of anaphylaxis, epinephrine should be administered without delay. According to AAFP, after administering epinephrine, clinicians should administer adjunctive treatment, including&#x000a0;corticosteroids, antihistamines,&#x000a0;and beta2 agonists. Referral to an allergist/immunologist should be considered.<xref ref-type="bibr" rid="article-17481.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17481.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ampicillin is a widely prescribed antimicrobial by&#x000a0;clinicians and other healthcare professionals working collaboratively as an interprofessional team. While the antimicrobial is effective, clinicians should not empirically&#x000a0;prescribe for all infections as the resistance to this agent is increasing globally.&#x000a0;Antimicrobial stewardship is a&#x000a0;coordinated program that promotes the appropriate use of antimicrobials. According to CDC, core elements of outpatient antimicrobial stewardship are commitment, action for policy and practice, tracking and reporting, education, and expertise.<xref ref-type="bibr" rid="article-17481.r36">[36]</xref></p>
        <p>Nephrology consultation is essential for hemodialysis. Pharmacists should verify dosing, look into the appropriateness of selecting ampicillin-sulbactam based on the infection type and available antibiogram data, and check for drug-drug interactions. In most cases,&#x000a0;nurses&#x000a0;administer this drug, monitor for adverse events, and assess therapeutic effectiveness, informing the clinician of their findings as treatment progresses. In the case of an overdose, emergency department physicians and nurses should rapidly stabilize the patient.&#x000a0;</p>
        <p>As outlined above, various healthcare providers, including clinicians (MDs, DOs, NPs, PAs), specialists, nurses, and pharmacists,&#x000a0;participate&#x000a0;in an interprofessional team-based approach to optimize patient care.&#x000a0;Additionally, antimicrobial stewardship is necessary for reducing global drug resistance. An&#x000a0;observational study of eight years involving&#x000a0;twenty-three antibiotics, including ampicillin, demonstrated that rates of&#x000a0;<italic toggle="yes">Clostridioides difficile</italic>&#x000a0;infection (CDI) could be reduced using interprofessional antimicrobial stewardship between clinicians, pharmacists, infection control nurses, and&#x000a0;other healthcare professionals.<xref ref-type="bibr" rid="article-17481.r37">[37]</xref>&#x000a0;[Level 3]</p>
      </sec>
      <sec id="article-17481.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17481&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17481">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17481/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17481">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17481.s11">
        <title>References</title>
        <ref id="article-17481.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaushik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borade</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Swami</surname>
                <given-names>OC</given-names>
              </name>
            </person-group>
            <article-title>Ampicillin: rise fall and resurgence.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2014</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>ME01</fpage>
            <page-range>ME01-3</page-range>
            <pub-id pub-id-type="pmid">24995206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biggs</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kucers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Penicillins and related drugs.</article-title>
            <source>Med J Aust</source>
            <year>1986</year>
            <month>Dec</month>
            <day>1-15</day>
            <volume>145</volume>
            <issue>11-12</issue>
            <fpage>607</fpage>
            <page-range>607-11</page-range>
            <pub-id pub-id-type="pmid">3540540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Karchmer</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Dajani</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bisno</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ferrieri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Durack</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association.</article-title>
            <source>JAMA</source>
            <year>1995</year>
            <month>Dec</month>
            <day>06</day>
            <volume>274</volume>
            <issue>21</issue>
            <fpage>1706</fpage>
            <page-range>1706-13</page-range>
            <pub-id pub-id-type="pmid">7474277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heintz</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Halilovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Vancomycin-resistant enterococcal urinary tract infections.</article-title>
            <source>Pharmacotherapy</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>1136</fpage>
            <page-range>1136-49</page-range>
            <pub-id pub-id-type="pmid">20973687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Threlfall</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Multidrug-resistant Salmonella typhi: a worldwide epidemic.</article-title>
            <source>Clin Infect Dis</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>24 Suppl 1</volume>
            <fpage>S106</fpage>
            <page-range>S106-9</page-range>
            <pub-id pub-id-type="pmid">8994789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bratzler</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Perl</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Auwaerter</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bolon</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Slain</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>RA</given-names>
              </name>
              <collab>American Society of Health-System Pharmacists</collab>
              <collab>Infectious Disease Society of America</collab>
              <collab>Surgical Infection Society</collab>
              <collab>Society for Healthcare Epidemiology of America</collab>
            </person-group>
            <article-title>Clinical practice guidelines for antimicrobial prophylaxis in surgery.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2013</year>
            <month>Feb</month>
            <day>01</day>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-283</page-range>
            <pub-id pub-id-type="pmid">23327981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osmon</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Berbari</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Berendt</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zimmerli</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Steckelberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hanssen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>WR</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e25</page-range>
            <pub-id pub-id-type="pmid">23223583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conde-Agudelo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Garcia S&#x000e1;nchez</surname>
                <given-names>&#x000c1;J</given-names>
              </name>
            </person-group>
            <article-title>Management of clinical chorioamnionitis: an evidence-based approach.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>223</volume>
            <issue>6</issue>
            <fpage>848</fpage>
            <page-range>848-869</page-range>
            <pub-id pub-id-type="pmid">33007269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum &#x003b2;-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Aug</month>
            <day>25</day>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-212</page-range>
            <pub-id pub-id-type="pmid">35439291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tipper</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Mode of action of beta-lactam antibiotics.</article-title>
            <source>Pharmacol Ther</source>
            <year>1985</year>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-35</page-range>
            <pub-id pub-id-type="pmid">3889939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penwell</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Giacobbe</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thresher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Huband</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>DeJonge</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Ehmann</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>1680</fpage>
            <page-range>1680-9</page-range>
            <pub-id pub-id-type="pmid">25561334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sullins</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Abdel-Rahman</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.</article-title>
            <source>Paediatr Drugs</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-117</page-range>
            <pub-id pub-id-type="pmid">23529866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Soeorg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tasa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Metsvaht</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kipper</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Herodes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oselin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hallik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ilmoja</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lutsar</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Ampicillin Pharmacokinetics During First Week of Life in Preterm and Term Neonates.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>464</fpage>
            <page-range>464-472</page-range>
            <pub-id pub-id-type="pmid">33591074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Temple</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Nahata</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Treatment of listeriosis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2000</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>656</fpage>
            <page-range>656-61</page-range>
            <pub-id pub-id-type="pmid">10852095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>e103</fpage>
            <page-range>e103-e119</page-range>
            <pub-id pub-id-type="pmid">30134425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>An Update Review on Listeria Infection in Pregnancy.</article-title>
            <source>Infect Drug Resist</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>1967</fpage>
            <page-range>1967-1978</page-range>
            <pub-id pub-id-type="pmid">34079306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Ampicillin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dicks</surname>
                <given-names>LMT</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Brandsborg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics.</article-title>
            <source>Curr Microbiol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>774</fpage>
            <page-range>774-782</page-range>
            <pub-id pub-id-type="pmid">30084095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirakian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leech</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Krishna</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Farooque</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Nasser</surname>
                <given-names>SM</given-names>
              </name>
              <collab>Standards of Care Committee of the British Society for Allergy and Clinical Immunology</collab>
            </person-group>
            <article-title>Management of allergy to penicillins and other beta-lactams.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>300</fpage>
            <page-range>300-27</page-range>
            <pub-id pub-id-type="pmid">25623506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pumphrey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ewan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fo&#x000eb;x</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gabbott</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jewkes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maconochie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rylance</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Unsworth</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Warrell</surname>
                <given-names>D</given-names>
              </name>
              <collab>Working Group of the Resuscitation Council (UK)</collab>
            </person-group>
            <article-title>Emergency treatment of anaphylactic reactions--guidelines for healthcare providers.</article-title>
            <source>Resuscitation</source>
            <year>2008</year>
            <month>May</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-69</page-range>
            <pub-id pub-id-type="pmid">18358585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurvits</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Black hairy tongue syndrome.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Aug</month>
            <day>21</day>
            <volume>20</volume>
            <issue>31</issue>
            <fpage>10845</fpage>
            <page-range>10845-50</page-range>
            <pub-id pub-id-type="pmid">25152586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Ampicillin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>10</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rutter</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations.</article-title>
            <source>Pharmacotherapy</source>
            <year>2017</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>593</fpage>
            <page-range>593-598</page-range>
            <pub-id pub-id-type="pmid">28247443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hornik</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Pencina</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tremoulet</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Capparelli</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Ericson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Cohen-Wolkowiez</surname>
                <given-names>M</given-names>
              </name>
              <collab>Best Pharmaceuticals for Children Act&#x02014;Pediatric Trials Network</collab>
            </person-group>
            <article-title>Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates.</article-title>
            <source>J Pediatr</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>178</volume>
            <fpage>125</fpage>
            <page-range>125-129.e1</page-range>
            <pub-id pub-id-type="pmid">27522443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massoll</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Betten</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Agranulocytosis occurrence following recent acute infectious mononucleosis.</article-title>
            <source>Am J Emerg Med</source>
            <year>2017</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>803.e5</fpage>
            <page-range>803.e5-803.e6</page-range>
            <pub-id pub-id-type="pmid">27912922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clabots</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Linn</surname>
                <given-names>FV</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Nosocomial Clostridium difficile colonisation and disease.</article-title>
            <source>Lancet</source>
            <year>1990</year>
            <month>Jul</month>
            <day>14</day>
            <volume>336</volume>
            <issue>8707</issue>
            <fpage>97</fpage>
            <page-range>97-100</page-range>
            <pub-id pub-id-type="pmid">1975332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oldfield</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment.</article-title>
            <source>Rev Gastroenterol Disord</source>
            <year>2004</year>
            <season>Fall</season>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>186</fpage>
            <page-range>186-95</page-range>
            <pub-id pub-id-type="pmid">15580153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Syu</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Correlation between drug-drug interaction-induced Stevens-Johnson syndrome and related deaths in Taiwan.</article-title>
            <source>J Food Drug Anal</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>427</fpage>
            <page-range>427-432</page-range>
            <pub-id pub-id-type="pmid">28911598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic-Induced Rash in Patients With Infectious Mononucleosis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>154</fpage>
            <page-range>154-162</page-range>
            <pub-id pub-id-type="pmid">27620494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heinz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The return of Pfeiffer's bacillus: Rising incidence of ampicillin resistance in Haemophilus influenzae.</article-title>
            <source>Microb Genom</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>4</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">30207515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuruvilla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to drugs.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2015</year>
            <month>May</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-19</page-range>
            <pub-id pub-id-type="pmid">25841553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>LV</given-names>
              </name>
            </person-group>
            <article-title>Sterile Basics of Compounding: Particulates in Parenteral Preparations: Sources, Minimization, and Detection.</article-title>
            <source>Int J Pharm Compd</source>
            <year>2022</year>
            <season>May-Jun</season>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-228</page-range>
            <pub-id pub-id-type="pmid">35657746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tenenbein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sitar</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Whole bowel irrigation as a decontamination procedure after acute drug overdose.</article-title>
            <source>Arch Intern Med</source>
            <year>1987</year>
            <month>May</month>
            <volume>147</volume>
            <issue>5</issue>
            <fpage>905</fpage>
            <page-range>905-7</page-range>
            <pub-id pub-id-type="pmid">3579442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jaar</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal Removal of Poisons and Toxins.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>06</day>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>1408</fpage>
            <page-range>1408-1415</page-range>
            <pub-id pub-id-type="pmid">31439539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>St&#x000fc;rmer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2017</year>
            <volume>173</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-60</page-range>
            <pub-id pub-id-type="pmid">28505618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanchez</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Fleming-Dutra</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Core Elements of Outpatient Antibiotic Stewardship.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2016</year>
            <month>Nov</month>
            <day>11</day>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">27832047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17481.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshida</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mataga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Otani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional Antimicrobial Stewardship Influencing <italic>Clostridioides difficile</italic> Infection: An 8-Year Study Using Antimicrobial Use Density.</article-title>
            <source>Infect Drug Resist</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>3409</fpage>
            <page-range>3409-3414</page-range>
            <pub-id pub-id-type="pmid">31807031</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
